Scientists have discovered the molecular basis for tamoxifen response in breast cancer cells - and the reason why some women can develop resistance to the treatment, according to a study published in Nature this week.
There is a new sense of optimism in cancer research. The translation of scientific advances in understanding the molecular and cellular biology of cancer into real benefits for patients is gathering pace, and great opportunities lie ahead in the development of powerful new approaches to diagnosis and treatment.
The Cancer Research UK Cambridge Centre unites more than 700 laboratory and healthcare professionals around a common mission to end death and disease caused by cancer, through research, treatment and education. As a CRUK Major Centre we serve as a national and international resource for patients with cancer and their families, researchers and health care providers, and cancer professionals in training
Professor Richard Gilbertson, Li Ka Shing Chair of Oncology, Head of the Department of Oncology, Director of the CRUK Cambridge Centre
The termly Research Horizons email lets you know when the latest issue of the University of Cambridge's research magazine is available to read online. Enter your name and email address below and select 'Subscribe' to sign up.
The University of Cambridge will use your name and email address to send you our termly Research Horizons email. We are committed to protecting your personal information and being transparent about what information we hold. Please read our email privacy notice for details.